The most commonly covered medications by health insurance in France

In France, the pharmaceutical landscape managed by Health Insurance reflects a constantly evolving health reality, where certain medications dominate due to their frequency of use and financial significance. Data from 2024-2025 confirm that the consumption of products such as paracetamol, respiratory treatments, and anti-inflammatories remains at the heart of public health priorities. These medications, often generic, benefit from widespread coverage, thus facilitating access to effective treatment. Furthermore, major players in the pharmaceutical industry such as Sanofi, Servier, Pfizer, and Roche play an essential role in supplying these products, highlighting a system where innovation, regulation, and social coverage seek to reconcile in a context of cost control.

The snapshot of the most reimbursed and prescribed medications also highlights a major economic challenge, that of controlling health expenditures in the face of sometimes excessive or inappropriate consumption. It is within this framework that health authorities and Health Insurance regularly publish detailed reports. This transparency helps identify trends, coordinate corrective measures when necessary, and understand the actual needs of the population. The 2024 ranking notably demonstrates how common molecules, sometimes intended for trivial conditions, can significantly impact the social security budget while already being an essential daily care.

Faced with this fragile balance, future issues concern both treatment quality, the emergence of new pathologies to treat, and masters of the risk of excess costs. This detailed analysis sheds light on the actors, treatments, and key figures that currently structure drug reimbursement in France.

Most reimbursed medications: an overview of the top 10 in France

The ranking of medications most covered by Health Insurance reveals a marked concentration on a few indispensable molecules for public health. At the top, unsurprisingly, are treatments based on paracetamol, such as Doliprane and Dafalgan, which constitute the cornerstone of symptomatic treatment for pain and fever. Their popularity is explained by their efficacy, generally good tolerance, and widespread prescription, including self-medication under supervision.

The list of reimbursed medications also features a predominance of chronic treatments and drugs for respiratory, digestive, or cardiovascular pathologies, underscoring the overall nature of French medical needs. Laboratories such as Sanofi, GSK (GlaxoSmithKline), and AstraZeneca are particularly involved in producing these products, benefiting from a market where therapeutic optimization is also a political goal.

• 💊 Paracetamol (Doliprane, Dafalgan)
• 💊 Bronchodilators (Ventoline)
• 💊 Antispasmodics (Spasfon)
• 💊 Statins (for cholesterol management)
• 💊 Antihypertensives
• 💊 Non-steroidal anti-inflammatory drugs (NSAIDs)
• 💊 Oral antidiabetics
• 💊 Antiallergics (inhaled corticosteroids)
• 💊 Psychotropic medications
• 💊 Antibiotics

Name of medication 🏥	Therapeutic class ⚕️	Manufacturing laboratory 🏢	Part covered by Health Insurance (%) 💰	Number of units sold in 2024 📦
Doliprane (paracetamol)	Analgesics	Sanofi	65%	45 million
Ventoline (salbutamol)	Bronchodilators	GSK	65%	13 million
Spasfon (phloroglucinol)	Antispasmodics	Servier	65%	9 million
Atorvastatin	Hypolipidemics	Pfizer	65%	8 million
Ramipril	Antihypertensives	Bayer	65%	7 million
Ibuprofen	NSAIDs	Roche	30%	15 million

It should be noted that coverage is based on rigorous criteria, also modulated depending on medical prescription and therapeutic context. For example, some medications, although very prescribed, see their reimbursement rate limited to 30%, such as ibuprofen, which remains a staple in the symptomatic treatment of inflammations.

Impact of medication coverage on the Health Insurance budget

The financial management of drug expenses is a crucial issue for French Health Insurance. In 2024, the share of medications in total health expenditure represents a substantial amount, accentuated by the high consumption of some highly prescribed treatments. The risk of budget overruns requires constant consolidation of reimbursement conditions and increased vigilance.

According to published figures, the twenty most reimbursed medicines account for nearly 28% of total pharmacy expenses, that is approximately 7.3 billion euros out of a total of 25.7 billion. This concentration illustrates the economic weight of these products within the French healthcare system and justifies efforts by laboratories and public authorities to negotiate prices, promote substitution with generics, and ensure rational use.

• 📊 Regular monitoring of expenses and transparency
• 🛡️ Call for reasoned prescription
• ⚖️ Budget correction measures in case of deviation
• 💡 Encouragement for the use of generics and biosimilars
• 🏛️ Involvement of laboratories (Sanofi, Bristol-Myers Squibb) in price negotiations

Year 📅	Total medication expenses 💶	Expenses of the top 20 reimbursed medications 💊	Share (%) of the key 20 medications in total expenses
2023	25.1 billion euros	7 billion euros	27.9%
2024	25.7 billion euros	7.3 billion euros	28.3%
Forecast 2025	26.3 billion euros	7.6 billion euros	28.9%

In this context, the role of pharmaceutical groups is twofold: they provide innovative treatments while being subject to price negotiations pressure. Among them, establishments like Novartis, Merck, and AstraZeneca are particularly active in seeking specialized medications that tend to increase costs despite the need to control expenditures.

The role of pharmaceutical laboratories in medication management

The pharmaceutical industry in France is dominated by a few major players who shape the therapeutic offerings covered by the Social Security system. Sanofi and Servier, two historical pillars, remain references in the production of essential medications, particularly in managing chronic and acute diseases. Additionally, multinational companies like Bristol-Myers Squibb, Pfizer, and Roche play a central role in therapeutic innovation and advanced treatments.

The relationships between laboratories and Social Security are characterized by regular price negotiations, influenced by the balance between innovation, mass prescription, and policy of expenditure control. This dynamic is essential to integrate pharmaceutical advancements while ensuring the economic viability of the system.

• 💼 Sanofi: market leader in paracetamol and vaccines
• 🎯 Servier: expert in cardiology and anti-inflammatory treatments
• 💊 Bristol-Myers Squibb: innovation in immuno-oncology
• 🎓 Pfizer: major provider of cardiovascular and antiviral treatments
• 🌍 Roche: pioneer in oncology and biotechnologies

Laboratory 💊	Main specialty 🏥	Market share in France (%) 📊	Notable contributions 💡
Sanofi	Analgesics, vaccines	18%	Doliprane, flu vaccines
Servier	Cardiology, antispasmodics	12%	Spasfon, medications for hypertension
Bristol-Myers Squibb	Oncology, immunology	10%	Innovative anti-cancer treatments
Pfizer	Cardiology, antivirals	15%	Atorvastatin, antiretroviral treatments
Roche	Oncology, biotechnology	14%	Oncological biologic treatments

It should be noted that this distribution remains fragile. The arrival of new molecules, withdrawal or limitation of certain products, and evolving medical practices regularly modify the landscape, forcing the Social Security to increase flexibility in management.

Generic and biosimilar medications: a key lever for cost containment

With a growing share in medication consumption, generics stand out as an essential lever for reducing expenses for Social Security. These medications, equivalent to the original branded drugs but marketed at lower cost, allow broader access to treatments without sacrificing quality. Laboratories such as Novartis, Bayer, or GSK (GlaxoSmithKline) offer a wide range in this field.

Additionally, biosimilars, which replace reference biological drugs, offer significant economic potential, especially in costly therapeutic areas like oncology or rheumatology. Their development is encouraged by public authorities through measures promoting prescription and dispensation.

• 💡 Generics: on average 30 to 70% cheaper than originals
• ♻️ Biosimilars: biological alternatives at lower cost
• 🏥 Easier access thanks to better coverage
• 📈 Progressive increase in their share of prescriptions
• 📉 Direct impact on reducing expenses

Type of medication 🧪	Notable examples 💊	Main laboratories 🤝	Impact on costs (%) 💰
Generics	Paracetamol, generic Ibuprofen	Novartis, Bayer, GSK	-40% to -70%
Biosimilars	biosimilar Trastuzumab	Pfizer, Roche	-20% to -40%

However, obstacles persist, notably linked to medical habits, laboratories’ communication policies, and public information. Deliberate actions aimed at strengthening confidence in these medications are already underway to ensure an economic shift beneficial to the entire French healthcare system.

Chronic treatments: a heavy weight in medication management

Among all prescriptions reimbursed by Health Insurance, treatments for chronic diseases constitute a significant share, due to their frequency and duration of use. Cardiovascular diseases, diabetes, chronic respiratory conditions, and mental disorders are the most affected segments.

The stability or even increase of these conditions in the French population contributes to maintaining a high level of medication consumption, sometimes exceeding budget management capacities. Regular monitoring of prescriptions is therefore a major challenge, combining control of proper use and therapeutic support.

• ❤️ Cardiovascular diseases: antihypertensives, statins
• 🩸 Diabetes: oral antidiabetics and insulins
• 🌬️ Chronic respiratory pathologies: bronchodilators, inhaled corticosteroids
• 🧠 Mental disorders: antidepressants, anxiolytics
• ⚖️ Monitoring and adapting treatments to limit overuse

Chronic disease 🏥	Main medicational class 💊	Annual prescriptions volume 📈	Evolution over 5 years (%) 📊
Hypertension	Antihypertensives (Ramipril, etc.)	27 million	+5%
Diabetes	Oral antidiabetics	18 million	+8%
Asthma	Bronchodilators (Ventoline)	12 million	+3%
Depression	Antidepressants	10 million	+6%

The coverage for these treatments is often total or close to 100%, recognizing the essential and prolonged character of care. This policy supports patients in their follow-up and compliance with prescriptions, to avoid costly complications sometimes resulting in hospitalization.

Medications for acute conditions: consumption and reimbursement

In addition to chronic treatments, medications used for acute illnesses remain essential in the therapeutic arsenal, whether for infections, sudden pains, or crises. These products, generally prescribed for a short duration, still account for a significant share of volumes consumed in urban areas.

The consumption of antibiotics, anti-inflammatories, or analgesics raises questions about rational use. The reimbursement policy aims to limit waste and resistance risks, while leaving sufficient access to effectively treat patients.

• 🦠 Antibiotics: still very prescribed despite awareness campaigns
• 🔥 NSAIDs: cautious management of reimbursement
• ❄️ Symptoms like fever and pain: paracetamol widely used
• 💉 Symptomatic treatments: analgesics and antispasmodics
• 🔎 Enhanced monitoring of rapidly dispensed prescriptions

Acute medication 🚑	⚕️ Class	Annual volume (in millions of boxes) 📦	Reimbursement rate (%) 💶
Amoxicillin	Antibiotics	6.5	65%
Ibuprofen	NSAIDs	15	30%
Doliprane (paracetamol)	Analgesics	45	65%
Spasfon	Antispasmodics	9	65%

The main challenge remains balancing necessary use and excess consumption or inappropriate use. Health authorities, in collaboration with pharmaceutical companies like Bayer or GSK, are working to establish training and information campaigns for healthcare professionals and the general public.

Regulation and criteria for coverage by the Health Insurance

Coverage of medications by Health Insurance is based on precise and evolving regulations, defined according to several key criteria: the transparency of therapeutic benefits, cost-effectiveness ratio, and medical necessity. Any new molecule or presentation must undergo a rigorous evaluation before being included in reimbursement.

This evaluation is notably ensured by the High Authority for Health (HAS), which determines the reimbursement rate based on service medical rendered (SMR) and the level of improvement in service medical rendered (ASMR). Adaptations are regularly implemented to accommodate pharmaceutical innovations and budget constraints.

• 📋 Evaluation by HAS based on SMR and ASMR
• 💰 Reimbursement rate varies from 15% to 100%
• 🔄 Periodic revision of reimbursements based on clinical data evolution
• 🚦 Promoting drugs with high medical service rendered
• 🧾 Transparency and priority for essential medications

Evaluation criteria 📊	Definition	Impact on management 🏥
Service Medical Rendered (SMR)	Therapeutic importance of a medication	Determines the reimbursement rate
Improvement of Service Medical Rendered (ASMR)	Comparison with existing medications	Influences price negotiations and reimbursement
Medication price	Set after negotiations with CEPS	Direct budget impact

The medium-term goal remains the rigorous control of the budget while maintaining fair access to treatments. Budget correction measures have already been launched to regulate price creation and expand the prescription of generics.

Therapeutic innovation and its integration into reimbursement

The regular emergence of innovative, sometimes revolutionary medications, raises major interest in coverage by Health Insurance. However, these high-cost treatments, often from advanced biotechnologies, pose a significant financial challenge. The French system must therefore balance promoting innovation and strict expenditure control.

Groups such as Novartis, Merck, AstraZeneca, and Roche are at the forefront of this dynamic, with advances in oncology treatments, rare diseases, or gene therapies. In collaboration with health agencies, the Social Security system implements experiments and protocols to integrate these innovations into an effective public health perspective.

• 🚀 Strong support for therapeutic innovation
• 💸 High costs requiring specific negotiations
• 🧪 Pilot projects and conditional reimbursement
• 👥 Collaboration between laboratories and health authorities
• 🔍 Ongoing analysis of benefits and cost-benefit impacts

Innovative medication 🚀	Main indication	Company 🎯	Average annual cost per patient (€) 💶
Targeted oncological treatments	Breast, lung cancer	Roche, Novartis	30,000 – 50,000
Gene therapy	Rare diseases	Sanofi, Novartis	300,000 – 500,000
Immunotherapy	Some cancers	Bristol-Myers Squibb	40,000 – 60,000

Research and development activities result in a constant evolution of the list of reimbursed medications, requiring close monitoring to ensure a balance between accessible medical progress and responsible management of public finances.

FAQ on the most covered medications by Health Insurance in France

• ❓ Which medications are reimbursed at 100%?
  Coverage at 100% mainly concerns vital medications or those associated with long-term conditions (LTC) such as treatments for diabetes or certain cancers.
• ❓ How is the reimbursement rate of a medication determined?
  The rate depends on the service medical rendered (SMR) and the improvement level (ASMR) assessed by HAS, as well as budgetary framework and negotiations with laboratories.
• ❓ Why do some highly prescribed medications have a low reimbursement rate?
  This may reflect a moderate or low service medical rendered, or a budget control policy aimed at limiting abuse, as is the case for some anti-inflammatories.
• ❓ Who are the main pharmaceutical laboratories in France?
  Leaders include Sanofi, Servier, Pfizer, Roche, Novartis, and Bayer, involved in most reimbursed treatments.
• ❓ Are generic medications as effective as original medications?
  Yes, generics contain the same active substance and must meet the same quality and efficacy standards as the original branded drugs.

For further information, readers are encouraged to refer to additional sources such as data published on Ameli Open Medic, or detailed analyses available via Les Furets and Le Monde.

The challenges in this sector concern both patients, healthcare professionals, and all economic and institutional actors, highlighting the complexity of the French pharmaceutical system and the need for continuous adaptation to present and future challenges.

Source: www.lesfurets.com